Moges Sisay, MD
Rheumatology · Evansville, INNPI 1649264896
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 188 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by Amgen at 29.1% of the total. Reporting peaked in 2021 at $919 and has fallen 87.5% since, to $115 in 2025. That places this record below the midpoint for rheumatology clinicians in IN, where the typical reported total is $2,585.
Across 188 payments — averaging $13.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$762
- Novartis$600
- AbbVie$600
- E.r. Squibb & Sons, L.L.C.$205
- Pfizer$144
- Mallinckrodt Hospital Products Inc.$58
- plus $245 from 11 others
Across 162 payments — averaging $11,371 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astrazeneca UK Limited$604K
- Novartis$516K
- Eli Lilly$293K
- AbbVie$213K
- GSK$206K
- Merck$10K
What the payments were for
- Food & beverage$2,602100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 81 | $762 |
| Novartis | 24 | $600 |
| AbbVie | 44 | $600 |
| E.r. Squibb & Sons, L.L.C. | 14 | $205 |
| Pfizer | 8 | $144 |
| Mallinckrodt Hospital Products Inc. | 2 | $58 |
| Boehringer Ingelheim | 2 | $41 |
| Sobi, Inc | 2 | $40 |
| Radius Health, Inc. | 2 | $30 |
| Bristol Myers Squibb | 2 | $28 |
| UCB, Inc. | 1 | $23 |
| Johnson & Johnson | 1 | $16 |
| Sanofi | 1 | $16 |
| AstraZeneca | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $14 |
| ADMA Biomanufacturing LLC | 1 | $13 |
| Organon | 1 | $10 |
How this compares
$2,613 in reported general payments places this provider in the 50th percentile of 106 rheumatology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 58 | $430,653 |
| EnbrelEtanercept | 38 | $268,822 |
| Humira(Cf) PenAdalimumab | 15 | $157,675 |
| Xeljanz XrTofacitinib Citrate | 19 | $142,502 |
| Cosentyx SyringeSecukinumab | 11 | $123,934 |
| Cosentyx (2 Syringes)Secukinumab | 14 | $106,837 |
| Humira PenAdalimumab | 13 | $88,084 |
| Orencia ClickjectAbatacept | 14 | $73,823 |
| OrenciaAbatacept | 12 | $64,243 |
| Hydroxychloroquine Sulfate | 756 | $21,801 |
| Leflunomide | 369 | $20,828 |
| MethotrexateMethotrexate Sodium | 693 | $13,981 |
| Mycophenolate Mofetil | 57 | $8,115 |
| Cevimeline Hcl | 15 | $3,193 |
| Prednisone | 393 | $2,820 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenEnbrel | $762 | $268,82238 claims |
| NovartisCosentyx (2 Syringes) | $600 | $106,83714 claims |
| E.r. Squibb & Sons, L.L.C.Orencia | $205 | $64,24312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 106 rheumatology providers in Indiana.
Other rheumatology in Evansville
- Theodore KortyEvansville$8K
- David BattIndianapolis$577K
- Kathleen ThomasNoblesville$511K
- Keith ReichDyer$193K
- Douglas SmithIndianapolis$147K
- Ahmad SalahMerrillville$139K
- Inna AroutiounovaIndianapolis$102K
- James CohenIndianapolis$76K
- Nina RamessarFort Wayne$75K
- Anita ZachariahMunster$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.